

# Update on long-term outcomes of a cohort of patients with *TCF3::HLF*-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation

## Authors

Aida Zeckanovic,<sup>1</sup> Brice Mouttet,<sup>2</sup> Luciana Vinti,<sup>3</sup> Philip Ancliff,<sup>4</sup> Benoît Brethon,<sup>5</sup> Gunnar Cario,<sup>6</sup> Sarah Elitzur,<sup>7</sup> Volkan Hazar,<sup>8</sup> Joachim Kunz,<sup>9</sup> Anja Möricke,<sup>6</sup> Jerry Stein,<sup>10</sup> Yöntem Yaman,<sup>11</sup> Jochen Buechner,<sup>12</sup> Magnus Aasved Hjort,<sup>13</sup> David O'Connor,<sup>4</sup> Angus Hodder,<sup>14</sup> Jack Bartram,<sup>4</sup> Julia Alten,<sup>15</sup> Draga Barbaric,<sup>16</sup> Gabriele Escherich,<sup>17</sup> Nicolas Boissel,<sup>18</sup> Loïc Vasseur,<sup>18</sup> Emmanuelle Clappier,<sup>19</sup> Laure Farnault,<sup>20</sup> Sarah Bonnet,<sup>21</sup> Katharine Patrick,<sup>22</sup> Martin Schrappe,<sup>6</sup> Sema Anak,<sup>8</sup> André Baruchel,<sup>5</sup> Franco Locatelli,<sup>3</sup> Martin Stanulla,<sup>23</sup> Arend von Stackelberg,<sup>24</sup> Nicole Bodmer<sup>1</sup> and Jean-Pierre Bourquin<sup>1</sup>


<sup>1</sup>Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland; <sup>2</sup>The Kaiya Foundation for Children with Very High Risk Leukemia, London, UK; <sup>3</sup>Department of Pediatric Hemato-Oncology, IRCCS Ospedale Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy; <sup>4</sup>Department of Hematology, Great Ormond Street Hospital, London, UK; <sup>5</sup>Department of Pediatric Hematology, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France; <sup>6</sup>Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany; <sup>7</sup>Pediatric Hematology-Oncology, Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel; <sup>8</sup>Department of Pediatric Oncology, Memorial Health Care, Private Medstar Yildiz Hospital, Antalya, Turkey; <sup>9</sup>Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany; <sup>10</sup>Bone Marrow Transplant Unit, Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel; <sup>11</sup>Department of Pediatric Hematology, Medipol University Hospital, Istanbul, Turkey; <sup>12</sup>Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway; <sup>13</sup>Department of Pediatric Hematology and Oncology, St. Olav's University Hospital, Trondheim,

Norway; <sup>14</sup>University College London Hospitals NHS Foundation Trust, London, UK; <sup>15</sup>Laboratory of Cytogenetics and Molecular Genetics, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany; <sup>16</sup>School of Clinical Medicine, UNSW Sydney, Sydney and Kids Cancer Center, Sydney Children's Hospital, Randwick, New South Wales, Australia; <sup>17</sup>Clinic for Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Germany; <sup>18</sup>Adolescent and Young Adult Hematology Unit, Saint Louis University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; <sup>19</sup>Hematology Laboratory, Saint Louis University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; <sup>20</sup>Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France; <sup>21</sup>Department of Hematology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; <sup>22</sup>Department of Hematology, Sheffield Children's Hospital, Sheffield, UK; <sup>23</sup>Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany and <sup>24</sup>Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany


Correspondence:  
J-P. BOURQUIN - Jean-Pierre.Bourquin@kispi.uzh.ch

<https://doi.org/10.3324/haematol.2024.286111>

Received: November 9, 2024.  
Accepted: January 28, 2025.  
Early view: February 6, 2025.

©2025 Ferrata Storti Foundation  
Published under a CC BY-NC license 

Supplemental figure 1: Survival curves



A: Overall survival; B: Event-free survival.